low molecular weight heparin

(redirected from Heparin, low-molecular-weight)

low mo·lec·u·lar weight hep·a·rin

(LMWH) (lō mŏ-lek'yŭ-lăr wāt hep'ăr-in)
A form of heparin with a longer half life and fewer adverse effects (e.g., thrombocytopenia).

low molecular weight heparin

Abbreviation: LMWH
The most bioavailable fraction of heparin. It has a more precise anticoagulant effect than unfractionated heparins and is used to prevent and treat deep venous thrombosis, pulmonary embolism, and acute coronary syndromes.


It should be used selectively, if at all, in patients with reduced kidney function.
See also: heparin
References in periodicals archive ?
The American College of Chest Physicians recommends therapeutic doses of intravenous unfractionated heparin, low-molecular-weight heparin, or fondaparinux for initial treatment of UEVT, followed by at least 3 months of treatment with a vitamin K antagonist.
A group of cardiologists and cardiovascular medicine specialists from the US, Europe, and Canada discuss therapies individually and in combination, including fibrinolytic agents; antiplatelet therapies like aspirin, thieneopyridines, and glycoprotein IIb/IIIa inhibitors; anticoagulant therapies such as unfractionated heparin, low-molecular-weight heparins, direct thrombin inhibitors, and synthetic factor X inhibitors; and therapies for non-ST-segment elevation ACS and ST-segment elevation myocardial infarction.
As expected, the new guidelines reaffirm the position of the American College of Chest Physicians that aspirin alone is not sufficient therapy to prevent venous thromboembolism in any patient population, because more effective alternatives are available, including heparin, low-molecular-weight heparin, and a synthetic, selective factor Xa inhibitor, fondaparinux, which was approved by the FDA in 2001.
Compared with unfractionated heparin, low-molecular-weight heparin (LMWH) is associated with a reduced risk of major bleeding and mortality in the treatment of DVT, and as such "should be used whenever possible for the initial inpatient treatment" of these patients, according to the treatment guidelines (Ann.
The drugs examined were heparin, low-molecular-weight heparin and glycoprotein lib-Ilia blockers (superaspirins).
Further analysis determined that only half of these at-risk patients (17,732) received ACCP-recommended types of prophylaxis, which include low-dose unfractionated heparin, low-molecular-weight heparin, graduated compression stockings, and/or intermittent pneumatic compression devices.
In 10 trials directly comparing low-molecular-weight with unfractionated heparin, low-molecular-weight heparin reduced risk of DVT (RR=0.
These important questions are answered in a guideline developed by a committee of the American College of Chest Physicians, which considered the following prophylaxis recommendations: early ambulation, aspirin, graduated compression stockings, intermittent pneumatic compression, low-dose unfractionated heparin, low-molecular-weight heparin, or oral antithrombotic agents.

Full browser ?